Drugs / Nazartinib
Nazartinib
also known as
EGF816 · EGF-816 MESYLATE TRIHYDRATE · NAZARTINIB MESYLATE · Nazartinib mesylate trihydrate · NVP-EGF816-AGA · NVP-EGF816-NX
Small molecule targets EGFR via inhibition
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03516214 | Apr 2018 → Sep 2022 | bronchial neoplasm | University of Cologne | Completed | No outcome recorded |
| Phase 1 | NCT03333343 | Jan 2018 → Oct 2026 expected | non-small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03114319 | May 2017 → Jul 2025 | cutaneous melanoma, esophageal squamous cell carcinoma, gastrointestinal stromal tumor, head and neck squamous cell carcinoma +1 | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02900664 | Aug 2016 → Mar 2021 | colorectal cancer, non-small cell lung carcinoma, triple-negative breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02335944 | Jan 2015 → Nov 2020 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT02108964 | Jun 2014 → Mar 2018 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT03292133 | Oct 2017 → Dec 2021 | lung cancer | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03040973 | Jul 2017 → Jul 2027 expected | — | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02323126 | Feb 2015 → Sep 2019 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | Met primary Stop: Enrollment |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nazartinib | “EGF816 (nazartinib) for oral administration” NCT03114319 ↗ |
| Known as | EGF-816 MESYLATE TRIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3787344 ↗ |
| Known as | EGF816 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03333343 ↗ |
| Known as | NAZARTINIB MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3787344 ↗ |
| Known as | Nazartinib mesylate trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3787344 ↗ |
| Known as | NVP-EGF816-AGA | ChEMBL registry synonym — accepted as the source's own label CHEMBL3787344 ↗ |
| Known as | NVP-EGF816-NX | ChEMBL registry synonym — accepted as the source's own label CHEMBL3787344 ↗ |
| Action | Inhibit | “selectively inhibits EGFR with Thr790Met or activating mutations (or both)” PMID 31954624 ↗ Jan 2020 |
| Modality | Small molecule | “a third-generation EGFR TKI” PMID 31954624 ↗ Jan 2020 |
| Route | Oral | “administered orally as a capsule” NCT02323126 ↗ |
| Target | EGFR | “selectively inhibits EGFR with Thr790Met or activating mutations (or both)” PMID 31954624 ↗ Jan 2020 |